- Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases
-
Ryu YJ, Chun EM, Lee SN, Shim SS
- KMID: 1705587
- Korean J Radiol.
- 2014 Apr;15(2):300-304.
- doi: 10.3348/kjr.2014.15.2.300
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is... -
- CITED
-
- Close
- SHARE
-
- Close
- Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
-
Cheon YH, Kim MJ, Kang MG, Kim HJ, Lee SS, Kim CY, Jeon DH, Kim YE, Lee GW
- KMID: 1728007
- Yonsei Med J.
- 2011 Jul;52(4):695-698.
- doi: 10.3349/ymj.2011.52.4.695
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous... -
- CITED
-
- Close
- SHARE
-
- Close
- Alfuzosin-induced Acute Liver Injury
-
Kim SY, Kim BH, Dong SH, Kim HJ, Chang YW, Chang R, Kim YW
- KMID: 760743
- Korean J Hepatol.
- 2007 Sep;13(3):414-418.
- doi: 10.3350/kjhep.2007.13.3.414
We describe a 56-year-old man who developed an acute liver injury after taking alfuzosin for 1 month to control his newly diagnosed benign prostatic hypertrophy (BPH). There was no history... -
- CITED
-
- Close
- SHARE
-
- Close
